Kuros Biosciences AG - ESG Rating & Company Profile powered by AI
This ESG score covers seventeen United Nations Sustainable Development Goals including: 'Zero Hunger', 'Industry, Innovation & Infrastructure' and 'Life on Land'. The article contains a Q&A table about Kuros Biosciences AG. This webpage is a free E,S&G assessment covering Kuros Biosciences AG.
Kuros Biosciences AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 4.0, social score of 1.3 and governance score of 4.6.
3.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Novartis AG | 9.2 | High |
2 | Daiichi Sankyo Co Ltd | 8.9 | High |
... | ... | ... | |
1659 | Vivo Cannabis Inc | 3.4 | Medium |
1659 | Verve Therapeutics Inc | 3.4 | Medium |
1705 | Kuros Biosciences AG | 3.3 | Medium |
1705 | Benitec Biopharma Ltd | 3.3 | Medium |
1705 | Entera Bio Ltd | 3.3 | Medium |
... | ... | ... | |
2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
2749 | Zyden Gentec Ltd | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Kuros Biosciences AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kuros Biosciences AG disclose current and historical energy intensity?
Sign up for free to unlockDoes Kuros Biosciences AG report the average age of the workforce?
Sign up for free to unlockDoes Kuros Biosciences AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kuros Biosciences AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kuros Biosciences AG disclose cybersecurity risks?
Sign up for free to unlockDoes Kuros Biosciences AG offer flexible work?
Sign up for free to unlockDoes Kuros Biosciences AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kuros Biosciences AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kuros Biosciences AG conduct supply chain audits?
Sign up for free to unlockDoes Kuros Biosciences AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kuros Biosciences AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kuros Biosciences AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kuros Biosciences AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kuros Biosciences AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kuros Biosciences AG disclose water use targets?
Sign up for free to unlockDoes Kuros Biosciences AG have careers partnerships with academic institutions?
Sign up for free to unlockDid Kuros Biosciences AG have a product recall in the last two years?
Sign up for free to unlockDoes Kuros Biosciences AG disclose incidents of discrimination?
Sign up for free to unlockDoes Kuros Biosciences AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kuros Biosciences AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kuros Biosciences AG disclose parental leave metrics?
Sign up for free to unlockDoes Kuros Biosciences AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kuros Biosciences AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kuros Biosciences AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kuros Biosciences AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kuros Biosciences AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kuros Biosciences AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kuros Biosciences AG involved in embryonic stem cell research?
Sign up for free to unlockDoes Kuros Biosciences AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kuros Biosciences AG disclose its waste policy?
Sign up for free to unlockDoes Kuros Biosciences AG report according to TCFD requirements?
Sign up for free to unlockDoes Kuros Biosciences AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kuros Biosciences AG disclose energy use targets?
Sign up for free to unlockDoes Kuros Biosciences AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kuros Biosciences AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kuros Biosciences AG
These potential risks are based on the size, segment and geographies of the company.
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.